Cancer Res: HDAC6 inhibitors may be able to effectively control the growth and cancer metastasis of triple-negative breast cancer.

Aug 11, 2020 // In a recent study published in the international journal Cancer Research, scientists from George Washington University and other institutions found that the genetic modification factor HDAC6 may help control tumor growth and slow cancer metastasis by studying triple-negative breast cancer in the body.
Photo Source: Public Domain Immunotherapy, a new type of cancer therapy that uses drugs to stimulate the body's own immune system to identify and destroy cancer cells, is now widely successful in treating melanoma and other cancers; Dr. Alejandro Villagra, a
researcher, said there is an urgent clinical need to develop new ways to increase the effectiveness of immunotherapy in the treatment of breast cancer, especially malignant, highly metastatic triple-negative breast cancer;
molecularally targeted formulations such as HDAC6 inhibitors have been described in many studies as cytotoxic, i.e. toxic to both cancer cells and healthy cells; the researchers found that these epigenetic drugs may have some informal regulatory properties, and then noted that inhibition of HDAC6 may have a strong and potential effect on the immune system, which does not appear to be related to previous cell toxicity due to HDAC inhibitors.
the first time in the study, researchers found that HDAC6 inhibitors not only improve patients' responses to immunotherapy, but also reduce breast cancer and have minimal toxic effects; Original origins from
: Debarati Banik, Satish Nopalonele, Melissa Hadley, et al, HDAC6 Plays a Noncanonical Role in The Regulation of Antitumor Immune Responses, Fellon, and SOrs OfoCancer, Cancer Research (2020). DOI: 10.1158/0008-5472.CAN-19-3738.